Vistagen Therapeutics (VTGN) Price to Sales (2012 - 2026)

Vistagen Therapeutics has disclosed Price to Sales across 9 years of filings, most recently posting 6.92 for Q2 2026.

• In Q2 2026, Price to Sales fell 97.25% year-over-year to 6.92; the TTM figure through Jun 2026 stood at 4.08 (down 95.71% YoY), while the FY2026 annual figure was 18.43, down 87.71% from the prior year.
• Price to Sales came in at 6.92 for Q2 2026 at Vistagen Therapeutics, down from 50.3 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 6571.43 in Q1 2022 to a low of 4859.62 in Q1 2025.
• Average Price to Sales over 5 years is 372.01, with a median of 213.44 recorded in 2025.
• Year-over-year, Price to Sales jumped 1525.02% in 2024 and tumbled 879.88% in 2025.
• Over 5 years, Price to Sales stood at 115.03 in 2022, then jumped by 193.81% to 337.98 in 2023, then increased by 7.66% to 363.86 in 2024, then plunged by 76.28% to 86.3 in 2025, then slumped by 91.99% to 6.92 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 6.92 in Q2 2026, 50.3 in Q1 2026, and 86.3 in Q4 2025.